Physician profile
Eric D Arnone
NPI 1447578943
$3,664.19
in general payments reported to CMS, 2019-2025
43 companies · $636 in 2025
The $636 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $838 · 2020: $397 · 2021: $146 · 2022: $484 · 2023: $586 · 2024: $578 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,800.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $730.56 | 2019-2025 | Botox, Lupron Depot |
| Astellas Pharma US INC | $609.09 | 2019-2025 | Xtandi, Myrbetriq |
| Sumitomo Pharma America, INC. | $245.62 | 2023-2025 | Gemtesa |
| Medtronic USA, INC. | $207.90 | 2019-2020 | |
| Axonics, INC. | $136.11 | 2022-2024 | Bulkamid, Axonics |
| Pfizer INC. | $132.24 | 2019-2024 | |
| Coloplast Corp | $131.84 | 2019-2023 | Altis |
| Caldera Medical, INC | $121.58 | 2022-2023 | Desara |
| Janssen Biotech, INC. | $86.40 | 2019-2023 | Erleada |
| Ferring Pharmaceuticals INC. | $80.28 | 2019-2025 | Adstiladrin |
| Medtronic, INC. | $79.08 | 2025 | Altaviva, Interstim |
| 180 Medical, INC. | $66.58 | 2019-2023 | Gentlecath Glide |
| Allergan, INC. | $63.14 | 2019-2021 | |
| Teleflex LLC | $62.76 | 2022-2024 | Urolift |
| Accord Healthcare, INC. | $59.53 | 2023 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Arnone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.